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BACKGROUND. Most basal cell carcinomas (BCCs) are indolent lesions; a few
become locally aggressive or even metastatic. Little is known about the molecular
and genetic alterations in this malignant transformation. Conventional karyotyp-
ing in BCC has revealed a high frequency of nonclonal, structural rearrangements,
with few cases that show multiple, unrelated, small clones suggestive of a multi-
cellular origin. Trisomy 6 was described recently in a few BCCs, but the biologic
significance of the appearance of trisomy 6 in BBCs was not clear.
METHODS. Thirty cases including 4 metastatic, 4 locally aggressive, and 22 conven-
tional nonaggressive BCCs were studied. Fluorescence in situ hybridization (FISH)
was performed on 4 mm tissue sections, using a-centromeric enumeration probes
for chromosome 6 (SpectrumGreen, Vysis Inc., Downers Grove, IL) and chromo-
some 4 (SpectrumOrange, Vysis Inc., Downers Grove, IL, used as disomic cell
control). Trisomy 6 was semiquantitated within tumor cells and nonneoplastic
cells in each case.
RESULTS. Trisomy 6 was identified in all 4 metastatic BCCs within tumor cells and in
corresponding BCCs at the primary cutaneous site in 2 of these 4 cases. Two locally
aggressive BCCs, 1 of which had preceding radiation exposure, also showed trisomy 6.
All nonaggressive BCCs and nonneoplastic cells were disomic for chromosome 6.
CONCLUSIONS. Trisomy 6 has been identified as a cytogenetic aberration represen-
tative of tumor cells in aggressive and metastatic BCC. None of the nonaggressive
BCCs in this study demonstrated trisomy 6. Acquisition of trisomy 6 by tumor cells
in BCC may lead to the emergence of metastatic potential. Additional studies to
define the underlying mechanisms may be valuable in preventing aggressive be-
havior in BCC. Cancer 2001;91:1927–32. © 2001 American Cancer Society.
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noma (BCC), metastatic BCC.
Basal cell carcinoma (BCC) in its sporadic form is one of the mostcommon neoplasms occurring in the white population. Most
BCCs are slow-growing, indolent lesions cured by complete excision.
However, a few BCCs (4%) recur regardless of the mode of therapy.1
BCC can metastasize, like any other carcinoma, although in less than
0.1% of cases2 BCCs at risk for metastasis are typically large, locally
aggressive, recalcitrant lesions on the head and neck, with regional
lymph nodes as the most common metastatic site.3
Histologically, the tumor is comprised of islands of basaloid cells,
often with a palisaded edge, surrounded by a characteristic stroma.
Little is known, however, about genetic or molecular alterations in
BCC, particularly those underlying the evolution of a truly malignant
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behavior in BCC. Point mutations in the p53 gene have
been observed both in BCC and in nonneoplastic sun
-exposed skin4 Loss of heterozygosity for loci on chro-
mosome 9q, where the gene for hereditary BCC is
located, has been observed in sporadic BCC.5 At the
present time, however, there is no definite evidence of
consistent cytogenetic or molecular alteration spe-
cific to sporadic BCCs. The problems associated with
solid tumor cytogenetics (insufficient mitoses, fibro-
blast overgrowth, poor chromosome banding) are
even more pertinent in this slow-growing tumor with
a prominent stromal component.6 Studies of short-
term BCC cultures6 –12 (harvested at 1–2 weeks) repeat-
edly have revealed a high frequency of nonclonal
structural rearrangements with multiple, small, unre-
lated, pseudodiploid clones within a single tumor
population. In addition, conventional karyotypic anal-
yses of nonneoplastic sun-exposed skin, both in the
vicinity of and away from the tumor, have revealed
similar cytogenetic changes, albeit in a lesser propor-
tion of cases compared with BCC.13,14
In a cytogenetic study of 22 BCCs, Jin et al.15
reported t(9;16)(q22;p13) as one of multiple, small
clones in 3 of 22 BCCs examined by conventional
methods following short-term culture. It is well recog-
nized that the results of conventional karyotyping in
solid tumors should be interpreted with caution,16,17
because it is difficult to be certain of the nature of the
cell that is demonstrating an aberration. A number of
questions still remain: 1) Are the observed cytogenetic
aberrations in BCC truly representative of the tumor
cell population and, if so, are they of pathogenetic
significance? 2) Do these aberrations have any corre-
lation with histologic type? 3) Is there a cytogenetic or
molecular event that underlies the evolution of meta-
static potential in BCC?
To avoid overgrowth by fibroblasts, efforts to an-
alyze direct preparations of BCCs (harvested at 24 – 48
hrs) have met with little success.18 Casalone et al19
found trisomy 6 in 5 of 25 direct preparations of BCC;
however, the significance of trisomy 6 in their BCC
cases was not clear.
The fluorescence in situ hybridization (FISH)
technique has the advantage of examining nondivid-
ing cells and, when performed on paraffin sections,
permits correlation of morphology with cytogenetic
findings. In the current study, trisomy 6 was demon-
strated as a cytogenetic aberration truly representative
of the tumor cells in BCC, and its presence was cor-
related with aggressive biologic behavior in BCC.
TABLE 1
Clinicopathologic Features of 22 Nonaggressive Basal Cell Carcinomas
No. Age/Gender Site Sizea Invasion Histology FISH
1 75 M Midchest 0.4 SD Superficial No 16
2 89 F Lower back 0.4 SD Superficial No 16
3 89 M Forehead 0.5 SD Superficial No 16
4 55 F Ear 1.9 DD Nodular No 16
5 69 M Cheek 0.4 SD Adenoid No 16
6 70 M Upper chest 0.9 SD Superficial No 16
7 65 F Upper lip 0.2 SD Solid No 16
8 72 M Preauricular 0.4 DD Solid No 16
9 76 M Upper arm 1.0 DD Adenoid No 16
10 68 M Shoulder 0.4 SD Superficial No 16
11 87 F Neck 0.3 DD Nodular No 16
12 86 M Upper lip 0.3 SD Nodular No 16
13 34 F Upper back 1.0 DD, SC Nodular No 16
14 62 M Forehead 0.5 SD Nodular No 16
15 79 M Chin 0.5 SD Nodular No 16
16 75 M Nasal ala 0.4 SD Nodular No 16
17 95 M Midback 0.9 DD, SC Nodular No 16
18b 80 M Forehead 0.5 DD Infiltrating No 16
19 74 F Forearm 1.1 DD Infiltrating No 16
20b 88 F Not known 0.6 DD Morphea No 16
21 89 F Lower lip 0.9 DD Nodular No 16
22 90 M Neck 0.4 DD Nodular No 16
FISH: fluorescence in situ hybridization; SD: superficial dermis; DD: deep dermis, SC: subcutis, 16: trisomy 6.
a Size in cm.
b No hybridization.
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MATERIALS AND METHODS
Patient Population
The surgical pathology files of Roswell Park Cancer
Institute were searched from 1994 –7 for metastatic
and locally aggressive BCCs. Four cases in each cate-
gory were retrieved and a review of the medical
records was performed. Cases included as nonaggres-
sive BCC (n 5 22) were sporadic, selected at random,
and included various histologic subtypes (Table 1).
Locally aggressive BCC (n 5 4, 2 of which were syn-
chronous lesions in 1 patient; Table 2) were defined
clinically based on size, depth of invasion, and diffi-
culty in management. In each case, a representative
formalin-fixed, paraffin-embedded, primary or meta-
static tumor block was selected by examination of the
original hematoxylin and eosin (H&E) sections while
confirming of the pathologic diagnoses. Paraffin
blocks from the corresponding BCC at the primary
cutaneous site were available in 2 of 4 metastatic cases
(Table 3, Cases 1 and 4). Two additional blocks were
retrieved from one metastatic BCC (Table 3, Case 3),
corresponding to nonneoplastic skin and benign
lymph nodes from the same surgical resection as the
metastatic lymph node.
Fluorescence In Situ Hybridization
Four mm sections were prepared for FISH by using a
paraffin pretreatment reagent kit (Vysis Inc., Down-
ers Grove, IL), according to the manufacturer’s in-
structions. FISH was performed using a-centro-
meric enumeration probes for chromosome 4
(D4Z1, CEP 4 SpectrumOrange, Vysis Inc.) and chro-
mosome 6 (D6Z1, CEP 6 SpectrumGreen, Vysis Inc.
simultaneously. Chromosome 4 was selected as an
internal control for disomic cells based upon the
absence of numeric aberrations of chromosome 4 in
reviewing previous cytogenetic studies of BCC. Co-
denaturation of probe and target DNA was accom-
plished at 85 °C for 1 minute, followed by overnight
hybridization at 42 °C, by using the HYBrite system
(Vysis Inc). Following posthybridization washes
0.43 in saline-sodium citrate buffer (SSC)/SSC/0.1%
NP-40 at 75 6 1 °C for 2 min, followed by 23 in
SSC/0.1% NP-40 at room temperature for 1 min), a
nuclear counterstain (DAPI II, Vysis Inc.) was ap-
plied, and sections were examined on a Nikon Op-
tiphot-2 (Nikon USA) epifluorescence microscope.
Each section was scanned (3150, DAPI filter) for
architectural morphology (Fig. 1) with visual quan-
titation of the probe signals at higher magnification
FIGURE 1. Nonaggressive superficial BCC (Table 1, Case 1) showing archi-
tectural morphology by nuclear counterstain (DAPI, original magnification,
3150). Inset: Cells with normal diploid signals for centromere 4 and 6 (CEP 4
SpectrumOrange/CEP 6 SpectrumGreen/DAPI, original magnification, 31500).
TABLE 2
Clinicopathologic Features of 4 Aggressive Nonmetastatic Basal Cell Carcinomas
No. Age/Gender Site Sizea Invasion Histology FISH Treatment Follow-up
1b 51 M Chin, neck, and
upper chest
19.0 Skeletal muscle Nodular Rare tumor cells 16 Surgery 1 RT AWNED at 8 mos
2b 52 M Forehead 1.0 Skeletal muscle Nodular 10% tumor cells 16 Surgery AWNED at 5 mos
3 54 M Earc 1.5 Cartilage Infiltrating No 16 Surgery AWNED at 18 mos
4 65 M Behind earc 2.0 Bone Infiltrating No 16 Surgery AWD at 4 mos
FISH: fluorescence in situ hybridization; 16: trisomy 6; RT: radiotherapy; AWD: alive with disease; AWNED: alive with no evidence of disease.
a Size in cm.
b Same patient.
c Recurrence.
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(31500 oil, single, dual, and triple bandpass filters).
In situ hybridization was considered successful if
easily visible probe signals were present in most or
all nuclei. At least 20 high-power fields (31500) or
the entire section, if small, were studied in areas
with minimal nuclear overlap and clearly defined
nuclear outlines. When present, the percentage of
tumor cells showing trisomy 6 was estimated. Non-
neoplastic cells, including surrounding stromal
cells, benign epithelium, skin appendages, and lym-
phocytes were studied in each case. The images
were captured using a monochrome CCD camera
(Cohu, Inc., San Diego, CA) and image analysis soft-
ware (MacProbe, Perceptive Scientific Instruments
Inc., League City, TX).
RESULTS
The clinicopathologic features of 22 conventional
nonaggressive, 4 aggressive, and 4 metastatic BCCs
are presented in Tables 1, 2, and 3 respectively. In
situ hybridization was accomplished in all cases
except 2 nonaggressive BCCs. Numeric abnormali-
ties of chromosome 4 were not observed in any case.
Trisomy 6 was not identified in any of the 20 non-
aggressive BCCs (example in Fig. 1) in this study.
Trisomy 6 was present in 2 aggressive BCCs in one
patient (Table 2, Cases 1 and 2); in rare tumor cells
in the initial BCC (Table 2, Case 1), and in a single
nodular focus within the synchronous tumor, over-
all constituting approximately 10% of tumor cells
(Table 2, Case 2, Fig. 2).
Trisomy 6 was identified in tumor cells within
metastatic sites from all 4 patients with metastatic
BCC (Table 3). The 3 lymph node metastatic foci dem-
onstrated trisomy 6 in a high proportion (50 – 80%) of
FIGURE 2. Locally aggressive BCC, nodular type (Table 2, Case 2) showing
trisomy 6 (arrows) in palisaded edge of tumor nodule (CEP 4 SpectrumOrange/
CEP 6 SpectrumGreen/DAPI, original magnification 31500).
TABLE 3




Primary basal cell carcinoma Metastases at time of study
Follow-upSite Sizea Histology FISH Site FISH
1 64 M Neckb 5.0 Infiltrating Rare tumor
cells 16
1 of 2 regional




1 yr, DOD at
2 yrs
2 69 M Ear helix
and face








3 74 M Shoulder 14.5 Adenoid NA 2 of 28 axillary










1 of 2 regional
LN at 5 yrs
60% tumor
cells 16c
AWD at 1 yr
FISH: fluorescence in situ hybridization; NA: not available for study; 16 5 trisomy 6; LN 5 lymph node; T4: thoracic 4 vertebra; DOD: dead of disease; AWNED: alive with no evidence of disease; AWD: alive with
disease.
a Size in cm.
b Recurrence.
c 5% cells with tetrasomy 6.
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tumor cells, whereas the intradermal metastatic lesion
had trisomy 6 in approximately 20% of tumor cells. In
1 lymph node with metastatic carcinoma (Table 3,
Case 4), about 5% of randomly distributed tumor cells
also demonstrated tetrasomy 6 (Fig. 3). In the 2 cor-
responding BCCs at the primary cutaneous site (Table
3, Cases 1 and 4), trisomy 6 was observed in rare and
about 50% of tumor cells, thus suggesting a direct
derivation of the metastatic tumor from the primary
site. In all cases, trisomy 6 was absent in stromal cells
adjacent to tumor and in cells of benign cutaneous
epithelium and appendages. Nonneoplastic cells in
additional sections of skin and benign lymph nodes in
1 metastatic BCC (Table 3, Case 3) were negative for
trisomy 6.
DISCUSSION
Most data in favor of a unicellular origin for neo-
plasms is based upon investigation of hematologic
and mesenchymal neoplasms20 In comparison, little is
known about karyotypic abnormalities in tumors of
epithelial origin21,22 The karyotypic pattern in most
epithelial neoplasms is characterized by multiple and
nonspecific aberrations, in contrast to hematologic
malignancies, which are characterized by simple and
disease-specific abnormalities.23 The cytogenetic and
molecular aberrations reported in BCC, and their sim-
ilarity with those observed in nonneoplastic skin indi-
cate an initial polyclonal process, perhaps a reflection
of cumulative DNA damage from exposure to sunlight.
In light of the frequent overgrowth of fibroblasts in
BCC cell cultures, these observed changes may not
even be representative of the tumor cell population in
BCC11
In this study, trisomy 6 was identified in tumor
cells from metastatic foci in all 4 patients studied and
in recurrences of BCC at the primary cutaneous site in
2 of these patients, thus suggesting a direct derivation
of tumor at the metastatic site from the primary site.
None of the 20 nonaggressive BCCs in this study
showed polysomy of chromosome 6. Evidence of tri-
somy 6 localization in the stromal cells or other non-
neoplastic cells adjacent to the epithelial component
of BCC was not identified in any of these cases. Of the
locally aggressive BCCs studied, trisomy 6 was ob-
served in 2 synchronous BCCs in the same patient.
The initial tumor was a long standing, large, 19 cm
BCC on the patient’s neck and upper chest, which was
treated by radiation therapy. While on treatment, a
second, small BCC developed on the patient’s fore-
head. This subsequent BCC demonstrated trisomy 6 in
1 nodular focus, predominantly at the palisaded edge
of the tumor (Fig. 2), whereas the nonneoplastic, cu-
taneous epithelium was disomic for chromosome 6.
In the abstract by Casalone et al.,19 there was no
discussion of the significance of trisomy 6, which was
detected in 5 of 25 BCC cases by the direct method. In
this study, the association of trisomy 6 with aggressive
biologic behavior in BCC was demonstrated. A review
of numeric abnormalities of chromosome 6 in neo-
plastic diseases indicates that trisomy 6 is associated
with increased aggressiveness in a few neoplasms. It
has been correlated with a higher grade of non-
Hodgkin lymphoma,24 and isochromosome 6p (func-
tional trisomy 6p) has been linked to tumor progres-
sion in retinoblastoma.25 In basal cell carcinomas,
trisomy 6 may be an initial or primary event occurring
in a few cases rendering the tumor cell more aggres-
sive, with acquisition of metastatic potential by a he-
matogenous or a lymphatic route. The etiologic agents
that trigger this genetic change are not yet well de-
fined. One predisposing factor may be radiation expo-
sure, which was identified in 1 patient with a trisomy
6 positive locally aggressive BCC in this study.
In conclusion, trisomy 6 is confirmed as a non-
random aberration occurring only within tumor cells,
and not stromal cells, in BCC. In this study, trisomy 6
is present only in BCCs that display aggressive biologic
behavior. Acquisition of trisomy 6 by tumor cells in
BCC may play a significant role in the emergence of
FIGURE 3. Metastatic BCC in regional lymph node (Table 3, Case 4) showing
tumor cells with trisomy 6 (small arrows) and tetrasomy 6 (large arrow). Inset:
Trisomy 6 in corresponding BCC at primary cutaneous site (CEP 4 Spectrum-
Orange/CEP 6 SpectrumGreen/DAPI, original magnification, 31500).
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metastatic potential. Additional studies to determine
the mechanism underlying this genetic event may
provide valuable practical insight in preventing the
emergence of aggressive behavior in this convention-
ally indolent neoplastic process.
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